TME Pharma first-half 2026 net loss narrows 76% to EUR 507,000

Bitget2026/10/30 16:55

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

TME Pharma’s first-half 2026 net loss narrowed 76% year over year to EUR 507,000.
Research and development expenses dropped 98% to EUR 21,000, while general and administrative expenses fell 79% to EUR 203,000.
Operating cash outflow declined 71% to EUR 831,000; cash and cash equivalents totaled EUR 1.02 million at June 30.
An October 29 exclusive negotiation agreement with TMS covers worldwide NOX-A12 rights and includes a EUR 150,000 non-refundable fee.
Debtholders agreed in October to extend debt maturity to June 2028; new bond financing totaled EUR 750,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TME Pharma NV published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

TME Pharma first-half 2026 net loss narrows 76% to EUR 507,000

You may also like

Crypto prices